Why the study?
Does statin medication affect pathological characteristics, biochemical recurrence, and functional outcomes in patients undergoing radical prostatectomy?
Population
588 patients undergoing radical prostatectomy, mean age 65.2 years (SD = 5.7 years)
Design
Cohort
Key result
Statin use for >2 years in radical prostatectomy patients was associated with a 2.76 times greater likelihood of higher pathological stage and a 5.39 times greater likelihood of Gleason score ≥7.
Authors
Loading...
Statin decisions pre-RP should remain unchanged; leaves open confounding versus causal effects on pathology.
Cohort (n=588)
Does statin medication affect pathological characteristics, biochemical recurrence, and functional outcomes in patients undergoing radical prostatectomy?
Odds Ratio: 2.76
In patients undergoing radical prostatectomy, long-term statin use is associated with lower preoperative PSA but more advanced pathologic stage, higher Gleason score, and increased risk of erectile dysfunction.
Kontraros et al. (2013) conducted a cohort in Prostate cancer (n=588). Statin therapy vs. No statin therapy was evaluated on Pathological stage pT3a to pT3b rather than pT2a to pT2c (OR 2.76). Statin use for >2 years in radical prostatectomy patients was associated with a 2.76 times greater likelihood of higher pathological stage and a 5.39 times greater likelihood of Gleason score ≥7.